Repros Reports Second Pivotal Androxal(R) Study Fully Enrolled Ahead Of Schedule

THE WOODLANDS, Texas, May 2, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq:RPRX) today announced it has fully enrolled the 180 subject second pivotal study (ZA-302) for Androxal® one month ahead of schedule. Androxal is being studied as an oral therapy for the treatment of secondary hypogonadism.

The Company expects to have topline results from the study during the fourth quarter of this year.

About Repros Therapeutics Inc.

Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

Any statements made by the Company that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including the ability to raise additional needed capital on a timely basis in order for it to continue to fund development of its Androxal ® and Proellex ® programs, have success in the clinical development of its technologies, the reliability of interim results to predict final study outcomes, and such other risks which are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov . Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please visit the Company's website at http://www.reprosrx.com .
CONTACT: Repros Therapeutics Inc.         Joseph Podolski (281) 719-3447         President and Chief Executive Officer                  Investor Relations:         Thomas Hoffmann         The Trout Group         (646) 378-2931

company logo

If you liked this article you might like

Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?

Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?

8 Stocks Under $10 to Trade for Huge Profits

8 Stocks Under $10 to Trade for Huge Profits

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

Repros (RPRX) Stock Plummets After FDA Rejects Hypogonadism Drug Trial Results

Repros (RPRX) Stock Plummets After FDA Rejects Hypogonadism Drug Trial Results

4 Stocks Under $10 to Trade for Big Breakouts

4 Stocks Under $10 to Trade for Big Breakouts